7-Nitroindazole | 2942-42-9
Catelog Number | A03-0007 |
Category | Nitric Oxide (NO) & Reactive Oxygen Species (ROS) |
Molecular Formula | C7H5N3O2 |
Molecular Weight | 163.14 |
Catalog Number | Size | Price | Quantity |
---|---|---|---|
A03-0007 | -- | $-- |
- Worldwide Delivery
- Quality Assurance
- 24/7 Customer Service
Product Introduction
7-Nitroindazole is a nitric oxide synthase inhibitor.
Chemical Information |
|
---|---|
Synonyms | 7-Nitroindazole (7-NI);1H-Indazole, 7-nitro-; NSC 72843 |
Purity | ≥98% by HPLC |
IUPAC Name | 7-nitro-1H-indazole |
Canonical SMILES | C1=CC2=C(C(=C1)[N+](=O)[O-])NN=C2 |
InChI | InChI=1S/C7H5N3O2/c11-10(12)6-3-1-2-5-4-8-9-7(5)6/h1-4H,(H,8,9) |
InChI Key | PQCAUHUKTBHUSA-UHFFFAOYSA-N |
Solubility | Soluble in DMSO (Slightly), Methanol (Slightly) |
Density | 1.525±0.06 g/cm3 |
Appearance | Pale Yellow to Yellow Solid |
Boiling Point | 383.3±15.0°C at 760 mmHg |
Melting Point | 186.5-187.5°C |
Product Specification |
|
---|---|
Storage | Store at -20°C |
Signal | Danger |
GHS Hazard Statements | H301 (86.67%): Toxic if swallowed [Danger Acute toxicity, oral] H315 (11.11%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (97.78%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H341 (11.11%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] H351 (86.67%): Suspected of causing cancer [Warning Carcinogenicity] H360 (86.67%): May damage fertility or the unborn child [Danger Reproductive toxicity] |
Precautionary Statement Codes | P203, P264, P264+P265, P270, P280, P281, P301+P316, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.) |
Computed Properties | |
---|---|
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 0 |
Exact Mass | 163.038176411 g/mol |
Monoisotopic Mass | 163.038176411 g/mol |
Topological Polar Surface Area | 74.5Ų |
Heavy Atom Count | 12 |
Formal Charge | 0 |
Complexity | 192 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently-Bonded Unit Count | 1 |
Compound Is Canonicalized | Yes |
Literatures
PMID | Publication Date | Title | Journal |
---|---|---|---|
36162621 | 2022-10-01 | N-isopropylbenzylamine, a methamphetamine mimics, produces toxicity via increasing nitric oxide in vitro | Toxicology |
23571415 | 2013-06-01 | Structure-based identification of OATP1B1/3 inhibitors | Molecular pharmacology |
22879052 | 2013-01-01 | Renal oxygenation and function of the rat kidney: effects of inspired oxygen and preglomerular oxygen shunting | Advances in experimental medicine and biology |
22877786 | 2012-12-01 | 7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson's disease | Neuropharmacology |
22884925 | 2012-12-01 | The differential role of NOS inhibitors on stress-induced anxiety and neuroendocrine alterations in the rat | Behavioural brain research |
Patents
Publication Number | Title | Priority Date |
---|---|---|
CN-114146092-A | Hyaluronic acid fragment, application of preparation thereof and quality control activity detection method | 2021-11-15 |
CN-113912542-A | Method for directly ammoniating nitro nitrogen heterocyclic compound | 2021-10-09 |
WO-2022239001-A1 | Pharmaceutical compositions for treating neurological conditions | 2021-05-10 |
US-2022331395-A1 | Extended-release injectable gel formulations containing angiotensin-(1-7) oligopeptides or variants thereof | 2021-04-07 |
WO-2022216941-A1 | Extended-release injectable gel formulations containing angiotensin-(1-7) oligopeptides or variants thereof | 2021-04-07 |
Applications of Fluorescent Probes & Dyes
Get More Product Details?
Related Products